GNMX - アエヴィ・ジェノミック・メディシン (Aevi Genomic Medicine Inc.) アエヴィ・ジェノミック・メディシン

 GNMXのチャート


 GNMXの企業情報

symbol GNMx
会社名 Aevi Genomic Medicine Inc (アエヴィ・ジェノミック・メディシン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Aevi Genomic Medicine Inc. formerly Medgenics Inc. is focused on genomic medicine. The Company is engaged in unlocking the potential of genomic medicine to translate genetic discoveries into therapies. The Company is engaged in developing therapies for children and adults with pediatric onset life altering diseases. The Company's product candidates include AEVI-001 and AEVI-002. The Company's research and development efforts leverage an internal genomics platform and a collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). .   アエヴィ・ジェノミック・メディシンは米国のバイオ医薬品企業。臨床段階で、遺伝子医療に従事する。同社は「注意欠陥・多動性障害(ADHD)」を治療する「NFC-1」を開発し、遺伝子異常に起因する「22q11.2欠失症候群」の治療にも取り組む。また、タンパク質の生産と配送を繰り返すために患者自身の皮膚を使う治療も開発する。本社はペンシルベニア州ウェイン。   Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engages in finding treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.
本社所在地 435 Devon Park Drive Suite 715 Wayne PA 19087 USA
代表者氏名 Michael F. Cola マイケル・F・コーラ
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 610-254-4201
設立年月日 36526
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 17人
url www.aevigenomics.com
nasdaq_url https://www.nasdaq.com/symbol/gnmx
adr_tso
EBITDA EBITDA(百万ドル) -32.65200
終値(lastsale) 1.245
時価総額(marketcap) 73879210.095
時価総額 時価総額(百万ドル) 71.20888
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 52.05788
当期純利益 当期純利益(百万ドル) -32.66400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aevi Genomic Medicine Inc revenues was not reported. Net loss decreased 11% to $16.9M. Lower net loss reflects Other General_Administration expense decrease of 13% to $3.8M (expense) Stock-based Compensation in SGA decrease of 12% to $889K (expense) Stock-based Compensation in R&D decrease of 16% to $646K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.51 to -$0.28.

 GNMXのテクニカル分析


 GNMXのニュース

   Aevi Genomic Medicine (NASDAQ:GNMX) Shares Down 7.7%  2019/11/13 05:20:14 Modern Readers
Aevi Genomic Medicine Inc (NASDAQ:GNMX) shares traded down 7.7% during mid-day trading on Tuesday . The company traded as low as $0.12 and last traded at $0.12, 1,020,600 shares traded hands during mid-day trading. A decline of 40% from the average session volume of 1,697,638 shares. The stock had previously closed at $0.13. Separately, ValuEngine […]
   The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts  2019/08/03 14:18:19 Benzinga
Biotech stocks went about in a steady manner this week amid a slew of big pharma and biotech earnings announcements, a handful of FDA approvals and a few clinical trial readouts. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) was a huge casualty as the micro-cap stock fell steeply on severing of a licensing pact with Sanofi SA (NASDAQ: SNY ). Here are the key catalysts that can sway biotech stocks in the unfolding week. Conferences SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference – Aug. 7, in Boston, Massachusetts Canaccord Genuity Growth Conference - Aug. 7-8, in Boston Clinical Trial Readouts Leap Therapeutics Inc (NASDAQ: LPTX ) is scheduled to provide an update on DKN-01 in combination with Merck & Co., Inc. (NYSE: MRK )'s Keytruda in ornithine transcarbamylase deficiency. Pending Mid-2019 Clinical Readouts Immunic Inc (NASDAQ: IMUX ) – interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis Conatus Pharmaceuticals Inc (NASDAQ: CNAT ) – 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis Alkermes Plc (NASDAQ: ALKS ) – Phase 3 top-line data for diroximel fumarate in relapsing remitting multiple sclerosis IMMUTEP LTD/S ADR (NASDAQ: IMMP ) – initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer and head and neck cancer Aevi Genomic Medicine Inc (NASDAQ: GNMX ) – Phase 1b data for AEVI-002 in pediatric …
   The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate  2019/07/27 18:32:10 Benzinga
Biotech stocks moved mostly sideways during the week, although there was a flurry of activity in the space. Earnings from the sector began to trickle in, with Bristol-Myers Squibb Co (NYSE: BMY ) reporting forecast-beating earnings. Intec Pharma Ltd (NASDAQ: NTEC ) and Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) lost much of their market value this week on clinical trial setbacks. The following are some of the key biotech catalysts in the upcoming week: Conferences 2nd Annual Biotechnology Congress: July 29-30 in Chicago. 8th International Conference on Stroke and Cerebrovascular Diseases: July 29-30 in Stockholm, Sweden. 27th International Congress on Cardiology and Medical Interventions: July 31-Aug. 1 in Chicago. Clinical Trial Readouts (mid-2019 releases) Immunic Inc (NASDAQ: IMUX ): interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis. Conatus Pharmaceuticals Inc (NASDAQ: CNAT ): 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis.
   Aevi Genomic's AEVI-001 flunks mid-stage ADHD study  2019/01/02 21:46:01 Seeking Alpha
   Aevi Genomic Medicine (NASDAQ:GNMX) Shares Down 7.7%  2019/11/13 05:20:14 Modern Readers
Aevi Genomic Medicine Inc (NASDAQ:GNMX) shares traded down 7.7% during mid-day trading on Tuesday . The company traded as low as $0.12 and last traded at $0.12, 1,020,600 shares traded hands during mid-day trading. A decline of 40% from the average session volume of 1,697,638 shares. The stock had previously closed at $0.13. Separately, ValuEngine […]
   The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts  2019/08/03 14:18:19 Benzinga
Biotech stocks went about in a steady manner this week amid a slew of big pharma and biotech earnings announcements, a handful of FDA approvals and a few clinical trial readouts. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) was a huge casualty as the micro-cap stock fell steeply on severing of a licensing pact with Sanofi SA (NASDAQ: SNY ). Here are the key catalysts that can sway biotech stocks in the unfolding week. Conferences SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference – Aug. 7, in Boston, Massachusetts Canaccord Genuity Growth Conference - Aug. 7-8, in Boston Clinical Trial Readouts Leap Therapeutics Inc (NASDAQ: LPTX ) is scheduled to provide an update on DKN-01 in combination with Merck & Co., Inc. (NYSE: MRK )'s Keytruda in ornithine transcarbamylase deficiency. Pending Mid-2019 Clinical Readouts Immunic Inc (NASDAQ: IMUX ) – interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis Conatus Pharmaceuticals Inc (NASDAQ: CNAT ) – 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis Alkermes Plc (NASDAQ: ALKS ) – Phase 3 top-line data for diroximel fumarate in relapsing remitting multiple sclerosis IMMUTEP LTD/S ADR (NASDAQ: IMMP ) – initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer and head and neck cancer Aevi Genomic Medicine Inc (NASDAQ: GNMX ) – Phase 1b data for AEVI-002 in pediatric …
   The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate  2019/07/27 18:32:10 Benzinga
Biotech stocks moved mostly sideways during the week, although there was a flurry of activity in the space. Earnings from the sector began to trickle in, with Bristol-Myers Squibb Co (NYSE: BMY ) reporting forecast-beating earnings. Intec Pharma Ltd (NASDAQ: NTEC ) and Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) lost much of their market value this week on clinical trial setbacks. The following are some of the key biotech catalysts in the upcoming week: Conferences 2nd Annual Biotechnology Congress: July 29-30 in Chicago. 8th International Conference on Stroke and Cerebrovascular Diseases: July 29-30 in Stockholm, Sweden. 27th International Congress on Cardiology and Medical Interventions: July 31-Aug. 1 in Chicago. Clinical Trial Readouts (mid-2019 releases) Immunic Inc (NASDAQ: IMUX ): interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis. Conatus Pharmaceuticals Inc (NASDAQ: CNAT ): 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis.
   Aevi Genomic's AEVI-001 flunks mid-stage ADHD study  2019/01/02 21:46:01 Seeking Alpha
   Aevi Genomic Medicine (NASDAQ:GNMX) Shares Down 7.7%  2019/11/13 05:20:14 Modern Readers
Aevi Genomic Medicine Inc (NASDAQ:GNMX) shares traded down 7.7% during mid-day trading on Tuesday . The company traded as low as $0.12 and last traded at $0.12, 1,020,600 shares traded hands during mid-day trading. A decline of 40% from the average session volume of 1,697,638 shares. The stock had previously closed at $0.13. Separately, ValuEngine […]
   The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts  2019/08/03 14:18:19 Benzinga
Biotech stocks went about in a steady manner this week amid a slew of big pharma and biotech earnings announcements, a handful of FDA approvals and a few clinical trial readouts. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) was a huge casualty as the micro-cap stock fell steeply on severing of a licensing pact with Sanofi SA (NASDAQ: SNY ). Here are the key catalysts that can sway biotech stocks in the unfolding week. Conferences SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference – Aug. 7, in Boston, Massachusetts Canaccord Genuity Growth Conference - Aug. 7-8, in Boston Clinical Trial Readouts Leap Therapeutics Inc (NASDAQ: LPTX ) is scheduled to provide an update on DKN-01 in combination with Merck & Co., Inc. (NYSE: MRK )'s Keytruda in ornithine transcarbamylase deficiency. Pending Mid-2019 Clinical Readouts Immunic Inc (NASDAQ: IMUX ) – interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis Conatus Pharmaceuticals Inc (NASDAQ: CNAT ) – 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis Alkermes Plc (NASDAQ: ALKS ) – Phase 3 top-line data for diroximel fumarate in relapsing remitting multiple sclerosis IMMUTEP LTD/S ADR (NASDAQ: IMMP ) – initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer and head and neck cancer Aevi Genomic Medicine Inc (NASDAQ: GNMX ) – Phase 1b data for AEVI-002 in pediatric …
   The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate  2019/07/27 18:32:10 Benzinga
Biotech stocks moved mostly sideways during the week, although there was a flurry of activity in the space. Earnings from the sector began to trickle in, with Bristol-Myers Squibb Co (NYSE: BMY ) reporting forecast-beating earnings. Intec Pharma Ltd (NASDAQ: NTEC ) and Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) lost much of their market value this week on clinical trial setbacks. The following are some of the key biotech catalysts in the upcoming week: Conferences 2nd Annual Biotechnology Congress: July 29-30 in Chicago. 8th International Conference on Stroke and Cerebrovascular Diseases: July 29-30 in Stockholm, Sweden. 27th International Congress on Cardiology and Medical Interventions: July 31-Aug. 1 in Chicago. Clinical Trial Readouts (mid-2019 releases) Immunic Inc (NASDAQ: IMUX ): interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis. Conatus Pharmaceuticals Inc (NASDAQ: CNAT ): 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis.
   Aevi Genomic's AEVI-001 flunks mid-stage ADHD study  2019/01/02 21:46:01 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アエヴィ・ジェノミック・メディシン GNMX Aevi Genomic Medicine Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)